Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 report from Bloomberg.
About 93% of GLP-1 ads from telehealth companies focused on thinness and downplayed risks, according to research from Boulder-based University of Colorado cited in the report. Off-label prescribing has increased significantly: Ozempic use among patients without obesity or diabetes rose from 3% in 2018 to 30% in 2023; Wegovy reached 38%.
Companies including EllieMD, Willow Health Services and Midi Health have marketed microdosing programs online and via social media, often through influencers. In addition, the CEOs Noom, Ro and Hims & Hers Health have acknowledged using GLP-1s for cosmetic reasons, the report said.
In September, the FDA issued around 100 cease-and-desist letters but did not directly address marketing to patients with low BMIs. Manufacturers Eli Lilly and Novo Nordisk have filed lawsuits over off-label promotion of their medications.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
